No Basis For FTC Lidoderm Pay-For-Delay Suit, Watson Says

The Federal Trade Commission maintains it has the authority to pursue a pay-for-delay suit over pain relief patch Lidoderm against Watson Laboratories Inc. in federal court, but its allegations should be...

Already a subscriber? Click here to view full article